From: IL2RA is associated with persistence of rheumatoid arthritis
Total (n = 645) | DMARD-free sustained remission achieved during follow-up (n = 119) | DMARD-free sustained remission not achieved during follow-up (n = 526) | |
---|---|---|---|
Baseline | |||
Age (years), mean (SD) | 56.9 (15.6) | 58.8 (16.9) | 56.5 (15.3) |
Female, n (%) | 430 (66.7) | 74 (62.2) | 356 (67.7) |
Symptom duration (weeks), median (IQR) | 18.8 (10.3–37.3) | 12.9 (7.3–28.6) | 20.3 (11.4–40.0) |
Swollen joint count in 66 joints, median (IQR) | 8 (4–13) | 9 (4–15) | 8 (4–13) |
CRP level (mg/l), median (IQR) | 18 (8–42) | 18 (8–43) | 18 (7–37) |
ACPA-positive, n (%) | 332 (52.5) | 15 (13.0) | 317 (61.3) |
RF-positive, n (%) | 371 (57.8) | 32 (27.1) | 339 (64.7) |
Follow-up | |||
Duration until DMARD-free sustained remission (years), median (IQR) | 4.3 (2.9–6.1) | N/A |